Clinical trials: Digestive System Diseases
Crohn Disease, Colitis, Ulcerative
A Study to Evaluate Disease Control, Treatment Patterns, Burden of Disease and Quality of Life in Participants With Moderate to Severe Inflammatory Bowel Disease (IBD)
The purpose of this study is to evaluate the percentage of moderate to severe IBD participants with active disease at Day 1.
- Conditions
- Crohn Disease, Colitis, Ulcerative, Inflammatory Bowel Disease
- Trial name
- RISE AR (NCT03488030)
- Where
- 7 sites in Argentina
- Volunteers
- 246 people
- Sponsor
- Takeda
Microsatellite Stable (MSS) Colorectal Adenocarcinomas, Colorectal Adenocarcinoma
Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer
The purpose of this study is to evaluate the safety and clinical activity of nivolumab and relatlimab in patients with metastatic or locally advanced microsatellite stable (MSS) colorectal cancer.
- Trial name
- NCT03642067
- Testing
- Nivolumab, Relatlimab
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Esophageal Squamous Cell Carcinoma
Adjuvant Pembrolizumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma at High Risk of Recurrence
In this study, participants with histologically diagnosed locally advanced esophageal squamous cell carcinoma who have received preoperative cisplatin-based chemoradiotherapy followed by surgery harbouring high risk of tumor…
- Trial name
- NCT03322267
- Testing
- Pembrolizumab
- Where
- Taiwan
- Volunteers
- 26 people
- Sponsor
- National Taiwan University Hospital
Non Alcoholic Steatohepatitis
Elafibranor, PK and Safety in Children and Adolescents 8 to 17 Years of Age With Non Alcoholic Steatohepatitis (NASH)
The study was being conducted in order to assess the pharmacokinetics and the safety of elafibranor following once daily administration of two dose levels of elafibranor (80 milligrams [mg] and 120mg) during 3 months in children…
- Trial name
- NCT03883607
- Testing
- Elafibranor 80mg, Elafibranor 120mg
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Genfit
Primary Sclerosing Cholangitis (PSC)
Simtuzumab (GS-6624) in the Prevention of Progression of Liver Fibrosis in Adults With Primary Sclerosing Cholangitis (PSC)
The purpose of this study is to evaluate whether simtuzumab (GS-6624) is effective at preventing the progression of liver fibrosis in adults with primary sclerosing cholangitis (PSC).
- Trial name
- NCT01672853
- Testing
- Simtuzumab
- Where
- 75 sites in United States, Belgium and 8 more
- Volunteers
- 235 people
- Sponsor
- Gilead Sciences
Crohn's Disease
Remicade® Crohn's Disease Registry Across Canada (Study P02793)
This registry is a multi-center, prospective, observational program that will gather and analyze data on subjects with Crohn's disease being treated with Remicade® as per approved product monograph in Canada.
- Trial name
- RemiTRAC® (NCT00755937)
- Testing
- Data collection post infusion
- Volunteers
- 556 people
- Sponsor
- Merck Sharp & Dohme LLC
Haemophilus Influenzae Type B, Hepatitis B
Study of Modified Process Hib/Hep B Vaccine in Infants (V121-019)(COMPLETED)
To determine if there is an improvement in the immune response to HBsAg (hepatitis B virus) in healthy infants using a modified process in a combination Haemophilus Influenzae, type b/Hepatitis B vaccine and a currently licensed…
- Trial name
- NCT00441012
- Testing
- Comparator: Modified Process Vaccine, Comparator: COMVAX™
- Volunteers
- 546 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Colorectal Cancer
Sym004 in Patients With Advanced Solid Tumors
This trial is designed as a multi-centre, open label, dose-escalation, phase I trial and consists of five parts.
- Trial name
- NCT01117428
- Testing
- Sym004
- Where
- 7 sites in United States, Belgium and 1 more
- Volunteers
- 111 people
- Sponsor
- Symphogen A/S
Carcinoma, Hepatocellular
A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular Carcinoma
The primary objective of this study is to evaluate the tolerability and safety of a combination of lenvatinib plus nivolumab in participants with hepatocellular carcinoma (HCC).
- Trial name
- NCT03418922
- Testing
- Lenvatinib, Nivolumab
- Where
- 6 sites in Japan
- Volunteers
- 30 people
- Sponsor
- Eisai Co., Ltd.
Chronic Pancreatitis, Insulin Resistance
Chronic Pancreatitis. Effect of Pioglitazone on Endocrine Function, Exocrine Function & Structure, Pain & Life Quality
The purpose of this study is to determine if study drug (Pioglitazone) treatment will improve pre-diabetes (insulin resistance) or ealy diabetes and improve clinical symptoms (pain) or laboratory evidence of chronic pancreatitis.
- Conditions
- Chronic Pancreatitis, Insulin Resistance, Normal or Mildly Abnormal Stool Fat Levels
- Trial name
- NCT00782795
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Colitis, Ulcerative
Safety, Tolerability, Efficacy and Dose-response of GSK2831781 in Ulcerative Colitis
This is a Phase 2, multicenter, randomized, double-blind, parallel group, placebo-controlled study to investigate the safety, tolerability, efficacy and dose-response of GSK2831781 in participants with moderate to severe active…
- Trial name
- NCT03893565
- Testing
- GSK2831781 - Double Blind Phase, GSK2831781 - Open Label phase
- Where
- 61 sites in United States, Bulgaria and 13 more
- Volunteers
- 104 people
- Sponsor
- GlaxoSmithKline
Advanced Gastrointestinal Stromal Tumors
Efficacy and Safety of PD-0332991 in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib
The treatment of advanced GIST patients is based on imatinib followed with sunitinib in case of resistance/intolerance. However, the median progression-free survival (PFS) on sunitinib is frequently short, and after failure with…
- Trial name
- CYCLIGIST (NCT01907607)
- Testing
- PD 0332991
- Where
- 9 sites in France
- Volunteers
- 29 people
- Sponsor
- Institut Bergonié
Surgery, Surgical Blood Loss
Association of Anemia With Hospital Costs in Elective Colorectal Surgery
The objective is to measure the adjusted association between preoperative anemia and total hospital costs. We hypothesize that patients with anemia before surgery will have higher hospitalization costs than people without anemia.
- Conditions
- Surgery, Surgical Blood Loss, Anemia, Colon Cancer
- Trial name
- NCT03476707
- Testing
- Anemia
- Volunteers
- 851 people
- Sponsor
- Ottawa Hospital Research Institute
Primary Biliary Cirrhosis
Pentoxifylline for Primary Biliary Cirrhosis
Primary biliary cirrhosis (PBC) is cholestatic liver disease characterized by progressive destruction of small bile ducts within the liver that can lead to end stage liver disease and all its complications.
- Trial name
- NCT01249092
- Testing
- Pentoxifylline
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- The Cleveland Clinic
Ulcerative Colitis (UC)
Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative Colitis
To evaluate safety and efficacy of two adalimumab dosing regimens for induction and maintenance (standard and higher dosing) in achieving clinical remission in subjects with moderately to severely active ulcerative colitis.
- Trial name
- NCT02065622
- Testing
- Adalimumab
- Where
- 173 sites in United States, Austria and 18 more
- Volunteers
- 952 people
- Sponsor
- AbbVie
Squamous Cell Carcinoma of the Anal Canal
Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).
This study is a Phase 3 global, multicenter, placebo-controlled double-blind randomized study that will enroll participants with inoperable locally recurrent or metastatic SCAC not previously treated with systemic chemotherapy.
- Trial name
- NCT04472429
- Testing
- carboplatin, paclitaxel, retifanlimab
- Where
- 84 sites in United States, Australia and 11 more
- Volunteers
- 308 people
- Sponsor
- Incyte Corporation
Gastroenteritis
Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Rotarix Porcine Circovirus (PCV)-Free Liquid Compared to Rotarix Liquid Given in 2-doses in Healthy Chinese Infants Starting at Age 6-16 Weeks
The purpose of this study is to evaluate the immunogenicity, reactogenicity and safety of the Porcine circovirus (PCV)-free liquid formulation of GlaxoSmithKline Biologicals' SA (GSK) oral live attenuated human rotavirus (HRV)…
- Trial name
- NCT06025695
- Testing
- GSK's liquid oral live attenuated HRV, PCV-free liquid formulation of GSK's oral live attenuated HRV
- Where
- 12 sites in China
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Biliary Tract Cancer (BTC)
A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract Cancer
A Phase 2, multicenter, open-label, 2-stage study to assess the safety, tolerability, and efficacy of XERMELO in combination with first-line (1L) therapy (cisplatin [cis] plus gemcitabine [gem])
- Trial name
- TELE-ABC (NCT03790111)
- Testing
- telotristat ethyl
- Where
- 14 sites in United States
- Volunteers
- 53 people
- Sponsor
- TerSera Therapeutics LLC
Gastrinoma, Glucagonoma
Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
This phase II trial is studying how well sorafenib tosylate works in treating patients with progressive metastatic neuroendocrine tumors.
- Conditions
- Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor
- Trial name
- NCT00131911
- Testing
- sorafenib tosylate
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Biliary Tract Cancer
NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer
This is a study to evaluate the clinical activity of the combination of fluorouracil, leucovorin, and nanoliposomal irinotecan as second-line treatment in patients with advanced biliary tract cancers following gemcitabine and…
- Trial name
- NCT04005339
- Testing
- Nanoliposomal Irinotecan, Leucovorin, Fluorouracil
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- Georgetown University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.